Therefore, TGF‐β‐induced TMEPAI is considered a crucial oncogenic coactivator of AKT and a promising target for developing molecular targeted therapy aimed at managing and treating PI3K/AKT signaling‐driven cancers. The gene discussed is AKT1; the disease is cancer.